Novartis AG Company Profile (NYSE:NVS)

About Novartis AG

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Exchange: NYSE
Symbol: NVS
CUSIP:

Key Metrics:

Previous Close: $80.88
50 Day Moving Average: $80.64
200 Day Moving Average: $78.59
52-Week Range: $69.90 - $95.11
Trailing P/E Ratio: 28.88
Foreward P/E Ratio: 15.77
P/E Growth: 2.78
Market Cap: $192.59B
Outstanding Shares: 2,381,221,000
Beta: 0.58

Profitability:

Net Margins: 13.84%
Return on Equity: 15.33%
Return on Assets: 8.66%

Debt:

Debt-to-Equity Ratio: 0.22%
Current Ratio: 0.90%
Quick Ratio: 0.65%

Additional Links:

Companies Related to Novartis AG:

Consensus Ratings for Novartis AG (NYSE:NVS) (?)

Ratings Breakdown:	2 Sell Ratings, 9 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Hold (Score: 2.13)
Consensus Price Target:	$93.50 (15.60% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)

Show:

Date	Firm	Action	Rating	Price Target
9/20/2016	Chardan Capital	Initiated Coverage	Buy	$95.00
9/13/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy
8/25/2016	Argus	Reiterated Rating	Hold
7/12/2016	Bank of America Corp.	Reiterated Rating	Hold
5/24/2016	Citigroup Inc.	Reiterated Rating	Neutral
5/13/2016	Jefferies Group	Reiterated Rating	Buy
5/2/2016	Leerink Swann	Reiterated Rating	Hold
4/22/2016	Barclays PLC	Upgrade	Underweight -> Equal Weight
4/14/2016	Credit Suisse Group AG	Reiterated Rating	Hold
4/12/2016	Morgan Stanley	Downgrade	Equal Weight -> Underweight
1/28/2016	BNP Paribas	Downgrade	Outperform -> Neutral
1/7/2016	Goldman Sachs Group Inc.	Boost Price Target	Neutral	$89.00 -> $92.00
11/23/2015	Vontobel	Downgrade	Hold
10/28/2015	Sanford C. Bernstein	Lower Price Target	Outperform	$102.00
10/28/2015	Main First Bank AG	Downgrade	Underperform
7/7/2015	Oddo Securities	Initiated Coverage	Buy
6/25/2015	HSBC	Initiated Coverage	Buy
6/22/2015	Bryan, Garnier & Co	Upgrade	Neutral -> Buy
3/4/2015	Natixis	Upgrade	Neutral -> Buy
1/5/2015	Cowen and Company	Upgrade	Market Perform -> Outperform	$95.00 -> $105.00
11/13/2014	Kepler Capital Markets	Upgrade	Hold -> Buy

(Data available from 9/28/2014 forward)

Earnings History for Novartis AG (NYSE:NVS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/19/2016	Q216	$1.18	$1.23	$12.33 billion	$12.47 billion	View	Listen
4/21/2016	Q116	$1.18	$1.17	$11.90 billion	$11.60 billion	View	Listen
1/27/2016	Q415	$1.18	$1.14	$12.64 billion	$12.52 billion	View	Listen
10/27/2015	Q315	$1.31	$1.27	$12.66 billion	$12.30 billion	View	Listen
7/21/2015	Q215	$1.20	$1.27	$12.45 billion	$12.70 billion	View	Listen
4/23/2015	Q115	$1.10	$1.33	$12.90 million	$11.94 billion	View	N/A
1/27/2015	Q314	$1.21	$1.21	$14.68 billion	$14.63 billion	View	N/A
10/28/2014	Q3	$1.31	$1.33	$14.51 billion	$14.70 billion	View	N/A
7/17/2014	Q214	$1.36	$1.36	$14.83 billion	$14.64 billion	View	N/A
4/24/2014		$1.27	$1.31	$14.25 billion	$14.02 billion	View	N/A
1/29/2014	Q413	$1.27	$1.20	$15.16 billion	$15.08 billion	View	N/A
10/22/2013	Q313	$1.31	$1.26	$14.28 billion	$14.34 billion	View	N/A
7/17/2013	Q213	$1.29	$1.30	$14.39 billion	$14.50 billion	View	N/A
4/24/2013	Q113	$1.28	$1.32	$14.02 million	$14.02 billion	View	N/A
1/23/2013	Q412	$1.19	$1.27	$14.42 billion	$14.80 billion	View	N/A
10/25/2012		$1.34	$1.34			View	N/A
7/19/2012		$1.33	$1.38			View	N/A
4/24/2012		$1.30	$1.27			View	N/A
1/25/2012		$1.26	$1.23			View	N/A
10/25/2011		$1.45	$1.45			View	N/A
7/19/2011		$1.46	$1.48			View	N/A
4/19/2011		$1.30	$1.41			View	N/A
1/27/2011		$1.25	$1.14			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Novartis AG (NYSE:NVS)

Current Year EPS Consensus Estimate: $4.76 EPS
Next Year EPS Consensus Estimate: $5.13 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	$1.17	$1.18	$1.17
Q2 2016	3	$1.12	$1.21	$1.17
Q3 2016	1	$1.19	$1.19	$1.19
Q4 2016	2	$1.13	$1.24	$1.19

(Data provided by Zacks Investment Research)

Current Dividend Information for Novartis AG (NYSE:NVS)

Annual Dividend:	$2.30
Dividend Yield:	2.84%
Dividend Growth:	2.40% (3 Year Average)
Payout Ratio:	82.14% (Based on Trailing 12 Months of Earnings) 48.32% (Based on Current Year Consensus EPS Estimate) 44.83% (Based on Next Year Consensus EPS Estimate)

Dividend History for Novartis AG (NYSE:NVS)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/1/2016	Annual	$2.34		2/24/2016	2/26/2016	2/26/2016
2/4/2014	annual	$2.72	3.48%	2/27/2014	3/3/2014	3/11/2014
2/11/2013	annual	$2.53	3.71%	2/26/2013	2/28/2013	4/5/2013

(Data available from 1/1/2013 forward)

Insider Trading History for Novartis AG (NYSE:NVS)

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.78%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/11/2016	Institutes For Biomed Novartis	Major Shareholder	Buy	277,777	$18.00	$4,999,986.00
2/17/2016	Bioventures Ltd Novartis	Major Shareholder	Buy	375,000	$8.00	$3,000,000.00
9/22/2014	Bioventures Ltd Novartis	Major Shareholder	Buy	325,000	$15.00	$4,875,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Novartis AG (NYSE:NVS)

Date	Headline
	10 Stocks John Rogers Keeps Buying (NYSE:NVS) finance.yahoo.com - September 27 at 6:24 PM
	Kite Pharma Reports Favorable Data from Lymphoma Study (NYSE:NVS) finance.yahoo.com - September 27 at 11:05 AM
	ETF’s with exposure to Novartis AG : September 26, 2016 (NYSE:NVS) www.capitalcube.com - September 26 at 6:35 PM
	Novartis Ilaris Approved for Extended Use in Periodic Fever (NYSE:NVS) finance.yahoo.com - September 26 at 11:11 AM
	Winning? We Review How Teva Dominates Generic Drug Space (NYSE:NVS) marketrealist.com - September 26 at 11:11 AM
	FDA OKs three new uses for Novartis' Ilaris - Seeking Alpha (NYSE:NVS) seekingalpha.com - September 24 at 10:55 AM
	UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure (NYSE:NVS) finance.yahoo.com - September 23 at 11:13 AM
	Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study (NYSE:NVS) finance.yahoo.com - September 23 at 11:13 AM
	Does Novartis AG (NVS) Have The Solution For Malaria? (NYSE:NVS) feedproxy.google.com - September 22 at 1:26 PM
	Does Novartis AG (NYSE:NVS) Have The Solution For Malaria? - Market Exclusive (NYSE:NVS) marketexclusive.com - September 22 at 11:19 AM
	Active Stocks Need to Consider- Novartis AG (NYSE:NVS), Calix Inc. (NYSE:CALX), Medovex (NASDAQ:MDVX) - Seneca Globe (NYSE:NVS) www.senecaglobe.com - September 21 at 10:37 AM
	Novartis' MS hopes expand after positive trial (NYSE:NVS) magseriesusa.net - September 20 at 11:45 AM
	GlaxoSmithKline Names Emma Walmsley as Next Chief Executive (NYSE:NVS) www.wsj.com - September 20 at 11:45 AM
	Novartis A Buy At Chardan (NYSE:NVS) www.benzinga.com - September 20 at 11:45 AM
	Chardan Capital Initiates Coverage on Novartis AG Common Stock (NVS) Setting A Rating Of “Buy” (NYSE:NVS) www.fidaily.com - September 20 at 11:45 AM
	Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope (NYSE:NVS) www.thecountrycaller.com - September 20 at 11:45 AM
	Breaking the mould: GSK picks Big Pharma's first female CEO (NYSE:NVS) in.finance.yahoo.com - September 20 at 11:45 AM
	Stocks Rallying on Glossy Earnings: Mylan N.V. (NASDAQ:MYL), Novartis AG (NYSE:NVS) - Street Wise Report (press release) (blog) (NYSE:NVS) streetwisereport.com - September 19 at 6:29 PM
	Can Novartis AG (ADR) (NVS) Survive with Alcon Crisis? - Smаrt Stоck Nеws (NYSE:NVS) www.smartstocknews.com - September 19 at 6:29 PM
	Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope - TCC (NYSE:NVS) www.thecountrycaller.com - September 19 at 6:29 PM
	Novartis (NVS) Presents Positive Data on Cardiovascular Drug (NYSE:NVS) finance.yahoo.com - September 19 at 11:00 AM
	AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months (NYSE:NVS) www.investopedia.com - September 17 at 10:57 AM
	Novartis Reports Positive Phase II Data on Migraine Drug (NYSE:NVS) finance.yahoo.com - September 16 at 10:00 AM
	Aperio Group LLC Decreased Stake in Novartis Ag Sponsored ... - Chester News (NYSE:NVS) www.chesterindependent.com - September 15 at 9:57 AM
	Health care stocks (NYSE:NVS) www.dlnnews.com - September 14 at 6:36 PM
	GSK Optimistic about Future of Its Consumer Healthcare Segment (NYSE:NVS) marketrealist.com - September 13 at 11:24 AM
	What’s the Problem with GSK’s Pharmaceutical Segment? (NYSE:NVS) marketrealist.com - September 12 at 11:05 AM
	How Can Pfizer Revive Its Essential Health Business? (NYSE:NVS) marketrealist.com - September 12 at 11:05 AM
	Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System (NYSE:NVS) www.nasdaq.com - September 8 at 6:15 PM
	Active Stocks in 'How' and 'Why'- Novartis AG (NYSE:NVS), Biomerica Inc. (NASDAQ:BMRA), Inphi Corporation (NYSE ... - Seneca Globe (NYSE:NVS) www.senecaglobe.com - September 8 at 10:19 AM
	Europe: New safe haven? (NYSE:NVS) finance.yahoo.com - September 7 at 6:39 PM
	Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent (NYSE:NVS) news.investornetwork.com - September 7 at 10:03 AM
	Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever (NYSE:NVS) finance.yahoo.com - September 6 at 6:40 PM
	2:49 am Novartis reports new data from FLAME study confirming Ultibro Breezhaler more effective than Seretide (NYSE:NVS) finance.yahoo.com - September 6 at 11:13 AM
	Novartis (NVS) Reports Positive Data on Ultibro Breezhaler (NYSE:NVS) finance.yahoo.com - September 6 at 11:13 AM
	The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been approved by FDA - TCC (NYSE:NVS) www.thecountrycaller.com - September 2 at 11:21 AM
	Top Earnings to Watch for: Novartis AG (NYSE:NVS) - The Voice Registrar (NYSE:NVS) voiceregistrar.com - September 2 at 11:21 AM
	Trending Stock - Novartis AG's (NVS) - Hot Stocks Point (NYSE:NVS) www.hotstockspoint.com - September 2 at 11:21 AM
	What Signal Is Novartis AG (NYSE:NVS) Sending Out With Its Cell Therapy Move? - Market Exclusive (NYSE:NVS) marketexclusive.com - September 2 at 11:21 AM
	Juno, Kite Pharma Fall After Novartis Dissolves CAR-T Unit (NYSE:NVS) www.pharmalive.com - September 1 at 6:28 PM
	Novartis to Dissolve Cell and Gene Therapy Unit (NYSE:NVS) www.pharmalive.com - September 1 at 9:41 AM
	What Signal Is Novartis AG (NYSE:NVS) Sending Out With Its Cell Therapy Move? (NYSE:NVS) marketexclusive.com - September 1 at 9:41 AM
	Novartis Rings Another Cell-Therapy Alarm Bell (NYSE:NVS) www.bloomberg.com - September 1 at 9:41 AM
	Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgens Enbrel (NYSE:NVS) news.investornetwork.com - September 1 at 9:41 AM
	Novartis AG (ADR) (NVS) Fights for Survival after Patent Expiration (NYSE:NVS) www.thecountrycaller.com - August 31 at 11:32 AM
	FDA Approves Novartis’s Biosimilar to Amgen’s Enbrel (NYSE:NVS) www.wsj.com - August 31 at 11:32 AM
	Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel (NYSE:NVS) finance.yahoo.com - August 31 at 11:32 AM
	Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words (NYSE:NVS) marketexclusive.com - August 31 at 11:32 AM
	Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration - TCC (NYSE:NVS) www.thecountrycaller.com - August 30 at 6:30 PM
	Novartis wins US OK for biosimilar version of Amgen's Enbrel (NYSE:NVS) sg.finance.yahoo.com - August 30 at 6:29 PM